Curaleaf Launches Hemp-Derived CBD Product Line in the U.S.

Curaleaf, Inc. (CSE: CURA) has announced this morning that the company is planning to launch their own line of domestically grown premium hemp-derived Cannabidiol (CBD) products called, Curaleaf Hemp. Their new product line will be distributed throughout the United States.

Currently, Curaleaf operates 33 cannabis dispensaries, 12 cultivation sites and 10 processing facilities in across 12 different states. They have focused their business model on setting up their operations in highly populated areas in states like Florida, Massachusetts, New Jersey and New York.

The new Curaleaf Hemp product line, which is available for purchase today, features:

  • Drops: CBD oil in droplet forms mixed with natural essential oils; available in Lemon Bergamot, Lavender Sweet Orange, Ginger Clove Cinnamon, Vanilla Ylang Ylang and Jasmine Wintergreen
  • Lotions: Topical cream for everyday pain relief; available in Lemongrass and Menthol
  • Soft-Gel Capsules: Convenient capsules perfect for daily use
  • Disposable Vape Pens: On-the-go vape pens; available in Lemon Bergamot, Lavender Sweet Orange, Ginger Clove Cinnamon, Vanilla Ylang Ylang and Jasmine Wintergreen

Their team of product developers have focuses on offering consumers all natural, non-toxic, CBD products that are manufacturing with the highest standards from industrial hemp grown in the U.S.

Joe Lusardi, President and Chief Executive Officer of Curaleaf, stated “Expanding our presence within the industry and entering the consumer goods marketplace with Curaleaf Hemp is an exciting step for the company. Patients already trust and rely on Curaleaf for the highest-quality medical cannabis products and we have taken that same care with the development of Curaleaf Hemp. Supporting overall wellness, Curaleaf Hemp is a consistent and reliable line of hemp-based CBD products that consumers can trust. We expect this to become a significant economic contributor to our business in the years to come.”

Related posts

Cash Crop Today Interview with CEO of Open Grow™ João Melo

Editor

MA & Associates LLC Cannabis Testing Laboratory Receives First Revenue; Schedules Additional Speaking and Sales Engagement

creativemind

U.S. Sales of Cannabis Projected to Reach $30 Billion by 2023 and $66.3 Billion by 2025

CCT IMPACT Agent

Leave a Comment

%d bloggers like this: